Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and potential post-approval market exclusivity for qualifying rare diseases.

Retinitis pigmentosa (RP) is a term for a group of eye diseases that can lead to loss of sight. What they have in common are specific changes your doctor sees when they look at your retina – a bundle ...

Retinitis pigmentosa is a devastating diagnosis. This condition can leave optometrists and ophthalmologists scrambling as they attempt to explain possible treatment options, none of which are very ...

According to Aldeyra Therapeutics, a phase 2/3 trial of ADX-2191 in patients with retinitis pigmentosa is expected to begin in 2025. The Food and Drug Administration (FDA) has granted Fast Track ...

Retinitis pigmentosa is characterised by changes in the pigment layer of the retina. The pigment layer of the retina invades and damages the nerve layer and with time it affects the blood vessels of ...

A report published Online First by Archives of Ophthalmology, one of the JAMA/Archives journals, reveals that adults with retinitis pigmentosa who took vitamin A supplements over a period of four to ...

OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

Ocugen, Inc. (NASDAQ:OCGN) is one of the High-Flying Penny Stocks to Buy. On March 11, Ocugen, Inc. (NASDAQ:OCGN) was ...

Researchers at the National Eye Institute have found that the complement system seems to protect against retinal degeneration in retinitis pigmentosa. The research contradicts previous findings, which ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted fast track designation to MCO-010 from Nanoscope Therapeutics for the treatment of retinitis ...